PA5-29507

antibody from Invitrogen Antibodies

Targeting: ACSL3 ACS3, FACL3, PRO2194

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-29507

Provider

Invitrogen Antibodies

Product name

ACSL3 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: 293T, A431, Jurkat, Raji. Predicted reactivity: Mouse (95%), Rat (95%), Pig (95%), Bovine (96%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.39 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression.

Rossi Sebastiano M, Pozzato C, Saliakoura M, Yang Z, Peng RW, Galiè M, Oberson K, Simon HU, Karamitopoulou E, Konstantinidou G
Science advances 2020 Oct;6(44)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of ACSL3 using 30 µg of A) 293T and B) A431 lysate. Samples were loaded onto a 7.5% SDS-PAGE gel and probed with an ACSL3 polyclonal antibody (Product # PA5-29507) at a dilution of 1:1000.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot using ACSL3 Polyclonal Antibody (Product # PA5-29507). Various whole cell extracts (30 µg) were separated by 7.5% SDS-PAGE, and the membrane was blotted with ACSL3 Polyclonal Antibody (Product # PA5-29507) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

ACSL3 Polyclonal Antibody detects ACSL3 protein at endoplasmic reticulum by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: ACSL3 stained by ACSL3 Polyclonal Antibody (Product # PA5-29507) diluted at 1:500.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

ACSL3 Polyclonal Antibody detects ACSL3 protein at cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded human breast carcinoma. ACSL3 stained by ACSL3 Polyclonal Antibody (Product # PA5-29507) diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of paraffin-embedded human breast cancer, using ACSL3 (Product # PA5-29507) antibody at 1:500 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 1 ACSL3 is overexpressed in human PDAC. ( A ) mRNA levels of ACSL3 in patient healthy tissue, primary PDAC, and PDAC metastasis from the subset GSE71729. Healthy pancreatic tissue: n = 46 patients, primary PDAC: n = 145 patients, and PDAC metastasis: n = 61 patients. Data are represented as box (Whisker's) plot. Dots evidence outliers according to Tukey's method. ( B ) mRNA levels of ACSL3 in patient primary PDAC and matched adjacent healthy tissue from the subset GSE62452 ( n = 60). Data are expressed as entire numbers normalized by global average. ( C ) Representative IHC staining for ACSL3 (top) and extracellular matrix deposition marker with Masson trichrome (blue, bottom) of a human TMA showing primary healthy tissue, PanIN, and primary PDAC. Scale bars, 50 mum. ( D ) ACSL3 IHC quantification (H-score) of TMA comparing PDAC and adjacent healthy tissue ( n = 50 samples). We considered an H-score of less than 100, from 100 to 200, and above 201 having a low, intermediate, or high staining intensity, respectively. ( E ) Stratification of the patients by tumor grade from (D). Healthy tissue, n = 50 samples; grade I, n = 5 samples; grade II, n = 23 samples; grade III, n = 22 samples. ( F ) Immunoblot for ACSL3, total RAS, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of five human patient-derived tumor samples and matched adjacent healthy tissue. ( G ) Correlation between ACSL3 and Masson trichrome staining of TMA from (C) and (D). Samples are divided in low, inte